Heartflow (NASDAQ:HTFL) Reaches New 52-Week High After Analyst Upgrade

Shares of Heartflow, Inc. (NASDAQ:HTFL) hit a new 52-week high during trading on Saturday after JPMorgan Chase & Co. raised their price target on the stock from $35.00 to $45.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Heartflow traded as high as $43.00 and last traded at $42.08, with a volume of 9908709 shares trading hands. The stock had previously closed at $31.01.

HTFL has been the subject of several other reports. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a report on Friday. Wells Fargo & Company increased their price target on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Friday. Weiss Ratings upgraded shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (up from $38.00) on shares of Heartflow in a research report on Friday. Finally, Canaccord Genuity Group increased their target price on Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.43.

Insider Activity

In other news, insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the sale, the insider owned 78,731 shares of the company’s stock, valued at $2,231,236.54. This trade represents a 10.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 38,900 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the transaction, the chief executive officer directly owned 457,935 shares of the company’s stock, valued at $16,027,725. The trade was a 7.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 115,805 shares of company stock worth $3,530,609 in the last 90 days. Company insiders own 7.70% of the company’s stock.

Key Headlines Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
• Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
• Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
• Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
• Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Institutional Trading of Heartflow

Several large investors have recently added to or reduced their stakes in the business. XXEC Inc. purchased a new stake in Heartflow during the second quarter valued at approximately $2,524,764,000. Wellington Management Group LLP boosted its stake in shares of Heartflow by 20.8% during the 4th quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock worth $171,812,000 after acquiring an additional 1,014,006 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Heartflow during the 2nd quarter valued at $152,502,000. Jupiter Topco LLC purchased a new stake in shares of Heartflow in the 2nd quarter worth $70,983,000. Finally, Bamco Inc. NY increased its stake in shares of Heartflow by 86.2% in the 4th quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock worth $67,158,000 after purchasing an additional 1,066,371 shares in the last quarter.

Heartflow Stock Performance

The company has a market capitalization of $3.63 billion and a P/E ratio of -22.99. The stock has a fifty day moving average of $29.08 and a 200 day moving average of $27.80.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.50% and a negative net margin of 55.82%.Heartflow’s revenue was up 47.7% compared to the same quarter last year. Research analysts anticipate that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.